H.C. Wainwright Downgrades Mirna, Inc. (MIRN) to Neutral

September 23, 2016 7:28 AM EDT
Get Alerts MIRN Hot Sheet
Price: $1.55 -2.52%

Rating Summary:
    1 Buy, 3 Hold, 0 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade MIRN Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

H.C. Wainwright downgraded Mirna, Inc. (NASDAQ: MIRN) from Buy to Neutral with a price target of $2.00 (from $6.00). The change follows news the company halted its MRX34 trial.

"Following the voluntary stop of the MRX34 trial, we are removing MRX34 sales from our estimates and downgrading MIRN from a Buy to Neutral. We believe Mirna may yet develop a compelling microRNA-based oncology drug, but we are uncertain about the delivery technology it may use and the miRNA target it may pursue. That said, we like that Mirna has a three-year cash runway to ruminate and refine its clinical development plans," said analyst Shaunak Deepak.

For an analyst ratings summary and ratings history on Mirna, Inc. click here. For more ratings news on Mirna, Inc. click here.

Shares of Mirna, Inc. closed at $1.96 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities

H.C. Wainwright

Add Your Comment